Product Description
A glycosylated form of a recombinant therapeutic agent which is chemically identical to or similar to an endogenous human granulocyte colony-stimulating factor (G-CSF). Produced endogenously by monocytes, fibroblasts, and endothelial cells, G-CSF binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/lenograstim)
Mechanisms of Action: G-CSF
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intravenous,Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Australia | Belgium | Bosnia | Brazil | Bulgaria | Cyprus | Denmark | Egypt | Finland | France | Germany | Greece | India | Indonesia | Ireland | Italy | Japan | Korea | Lithuania | Luxembourg | Malta | Morocco | New Zealand | Pakistan | Peru | Portugal | Russia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Kingdom | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: OSPEDALEN RAFFAELE
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: France
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CARDIOSTEM | P1 |
Recruiting |
Healthy Volunteers |
2024-12-31 |